Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Palisade Bio, Inc. (PALI)
Company Research
Source: Yahoo! Finance
– Formation of Clinical Advisory Board – Sufficient cash on hand to execute on business plan and achieve significant clinical milestones into 2025 Carlsbad, CA, March 27, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update. Recent Highlights The Company formed its Clinical Advisory Board and appointed preeminent Key Opinion Leaders, Bruce Sands, MD, MS and Florian Rieder, MD; The exercise in February 2024, of 3,422,286 previously issued warrants to purchase common stock resulting in gross cash proceeds to the Company of $2.5 million; Presentation of positive preclinical data of its lead asset, PALI-2108 at the 2024 Crohn's & Colitis Congress; and Giiant Pharma
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesGlobeNewswire
- Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.MarketBeat
- Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) [Yahoo! Finance]Yahoo! Finance
- Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)GlobeNewswire
PALI
Sec Filings
- 5/3/24 - Form 8-K
- 4/10/24 - Form 8-K
- 3/29/24 - Form S-3
- PALI's page on the SEC website